alexa Validation of the Hartford nomogram in trauma surgery patients.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Finnell DL, Davis GA, Cropp CD, Ensom MH

Abstract Share this page

Abstract OBJECTIVE: To validate the Hartford nomogram for once-daily aminoglycoside dosing in trauma surgery patients. METHODS: A chart review was performed in trauma surgery patients who were started on once-daily aminoglycoside therapy. A peak aminoglycoside concentration was drawn 30 minutes after the end of the first or second infusion, and a random concentration was drawn approximately 10 hours after the dose. The 10-hour random concentration was used to validate the Hartford nomogram by predicting the actual dosing interval (determined by extrapolating the peak and random concentrations to achieve a trough concentration <1 mg/L). The percentage of intervals accurately predicted by the nomogram was determined. RESULTS: Forty-nine patients (34 men and 15 women), age 43.0+/-15.9 y, total body weight 81.3+/-24.5 kg, ideal body weight 68.1+/-10.7 kg, dosing body weight (DBW) 72.0+/-14.4 kg, and estimated creatinine clearance [Cl(cr)] 89.5+/-20.6 mL/min/1.73 m2 were evaluated. Patients received 505+/-105 mg (7.0+/-0.4 mg/kg) of either gentamicin or tobramycin per dose. The concentration 30 minutes after the infusion was 22.4+/-5.9 mg/L, the concentration at the end of the dosing interval was 0.20+/-0.46 mg/L, the 10-hour random concentration was 2.6+/-1.8 mg/L, the elimination rate constant was 0.26+/-0.08 h(-1), the elimination half-life was 3.0+/-1.2 hours, and the volume of distribution was 19.9+/-7.9 L (0.28+/-0.09 L/kg of DBW). Ninety-eight percent (48/49) of the intervals were accurately predicted by the nomogram. CONCLUSIONS: In trauma surgery patients with Cl(cr) of more than 60 mL/min/1.73 m2, the Hartford nomogram using a single random aminoglycoside concentration accurately predicted the same once-daily aminoglycoside intervals as determined by two concentrations. Less aggressive therapeutic drug monitoring in this patient subpopulation can lead to significant cost savings.
This article was published in Ann Pharmacother and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected].com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords